Samsung Pharm files for MFDS approval to amend GV1001 PSP Phase 2b/3 trial plan

Bitget2026/09/28 08:55

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Samsung Pharm filed a protocol amendment for its domestic Phase 2b/3 trial of GV1001 in progressive supranuclear palsy-Richardson’s syndrome.
Submission to South Korea’s MFDS was dated Sept. 28, 2026; the trial targets 360 patients with a 72-week primary endpoint.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Samsung Pharm. Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20260928800667), on September 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Samsung Pharm files for MFDS approval to amend GV1001 PSP Phase 2b/3 trial plan

You may also like

Crypto prices